Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
From BioSpace · · 21 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.